* First presentation of interim data on Lambda in combination with the
direct-acting antiviral (DAA) daclatasvir, from the global D-LITE study of
genotype 1 patients
* Data from a separate Phase IIb study, EMERGE, continue to demonstrate
comparable SVR24 rates and further illustrate the safety and tolerability
profile of Lambda vs. alfa interferon in genotype 1 and 4 patients
* Phase III development of Lambda in combination with other antivirals
underway, and in combination with daclatasvir and ribavirin to initiate in
2013
Bristol-Myers Squibb Company BMY today announced for the first time
interim results from the global, D-LITE Phase IIb study, in which a 24-week
regimen combining the investigational compound Peginterferon lambda-1a
(Lambda) with the investigational direct-acting antiviral (DAA) daclatasvir
(DCV) and ribavirin (RBV), achieved sustained virologic response 12 weeks
post-treatment (SVR[12]) in 93% (13/14) of treatment-naïve, genotype 1b
chronic hepatitis C patients who achieved a protocol-defined response (PDR)^1.
The SVR12 rate for all genotype 1 infected patients in the Lambda/RBV/DCV
group was 76% (28/37). These study findings were presented in a late breaker
presentation at the American Association for the Study of Liver Diseases
(AASLD) congress in Boston. The Company also presented SVR[4] results from the
D-LITE Japanese sub-study, where all subjects were infected with HCV genotype
1b and SVR[12 ]was 100%. SVR results from the EMERGE Phase IIb study of Lambda
versus alfa interferon (alfa) in treatment-naïve genotype 1 or 4 patients were
also presented.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in